Latest Healthcare News

Page 1 of 197
BCAL Diagnostics is prepared to support an expedited Genetic Signatures and Microba merger, but only on revised terms, a GSS board reset and protections for a superior proposal. It may also provide up to $2 million in working capital to Microba, subject to raising the funds itself.
Ada Torres
Ada Torres
19 Nov 2026
Resonance Health delivered a $1.5 million profit and positive operating cash flow in every quarter of FY26, while raising $6 million to accelerate three growth programmes. The challenge is replacing a MASH trial that generated 48% of last year’s revenue.
Ada Torres
Ada Torres
19 Nov 2026
Actinogen Medical’s pivotal XanaMIA trial produced a mixed result: Xanamem showed a small, non-significant benefit across the full 247-patient population, but a prespecified older-patient analysis found a statistically significant difference in disease stabilisation. The company will continue its open-label extension, suspend future Phase 3 spending and seek development partners.
Victor Sage
Victor Sage
19 Nov 2026
Oceania Healthcare has moved Cash Flow from Existing Operations into a NZ$0.4 million inflow, while underlying EBITDA rose 18% to NZ$49.0 million in the six months to 30 September 2026. The turnaround came with stronger resales, higher care occupancy and lower costs, although the company remained loss-making on a statutory basis and withheld its interim dividend.
Victor Sage
Victor Sage
19 Nov 2026
Expeditors has outlined a long-term growth model targeting 5% to 7% annual revenue growth and 12% to 15% EPS growth. The logistics group also issued Q4 and full-year 2026 EPS guidance while flagging artificial intelligence, automation and potential acquisitions as part of its growth plan.
Maxwell Dee
Maxwell Dee
19 Nov 2026
ParagonCare says it achieved its FY26 guidance and lifted underlying EBITDA 16.5% to $97.2 million, despite a statutory earnings hit from the Infinity Pharmacy Group bad debt. The healthcare distributor is now turning to Asian expansion, operational efficiency and an active share buyback in FY27.
Ada Torres
Ada Torres
18 Nov 2026
Genetic Signatures has abandoned its proposed merger with Microba Life Sciences after Microba said it lacked the financial capacity to complete the transaction without fresh capital. GSS also declined to provide unsecured working capital funding, leaving the shareholder vote and Takeovers Panel process to be unwound separately.
Ada Torres
Ada Torres
18 Nov 2026
Genetic Signatures has ended its proposed merger with Microba Life Sciences after Microba said it could not complete the transaction without raising more capital. The decision also removes the deal’s shareholder vote and leaves a Takeovers Panel application awaiting clarification.
Ada Torres
Ada Torres
18 Nov 2026
Cann Group says its balance-sheet repair and cost cuts have created room for growth, with September-quarter revenue and exports jumping. But the medicinal cannabis producer remains loss-making on a normalised basis and is now under pressure to turn improving sales into consistently positive cash flow.
Ada Torres
Ada Torres
18 Nov 2026
Vital Infrastructure will sell about 95.9 million Vital Healthcare units for net proceeds of C$123.7 million, reducing its holding to approximately 11.9%. The proceeds are earmarked for debt repayment and North American healthcare property acquisitions.
Eva Park
Eva Park
18 Nov 2026
Infratil lifted FY27 operating EBITDAF guidance after a 28% first-half increase, led by data centres, renewables and One NZ. But the growth came with a NZ$247.8 million loss attributable to shareholders, a NZ$256 million incentive-fee provision and a sharp increase in capital spending.
Victor Sage
Victor Sage
18 Nov 2026
Viatris has completed its US$1.69 billion cash acquisition of Pacira BioSciences, taking full ownership of the non-opioid pain management company. Pacira is expected to contribute US$90 million to US$100 million in revenue over the remainder of 2026.
Victor Sage
Victor Sage
18 Nov 2026

Browse the archive

Full archive